

## Philippines : Second Health System Enhancement to Address and Limit COVID-19 Under the Asia Pacific Vaccine Access Facility – Additional Financing (HEAL2-AF)

### 1. Project Information

Project ID:	P000555	Instrument ID:	L0555A
Member:	Philippines	Region:	South-Eastern Asia
Sector:	CRF-Public Health	Sub-sector:	
Instrument type:	<input checked="" type="checkbox"/> Loan:250.00 US Dollar million <input type="checkbox"/> Guarantee	Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Department of Finance, Philippines
Implementing Entity:	Department of Health, Philippines		
Project Team Leader:	Yuka Terada (Responsible DG: Rajat Misra; Responsible Department: INF1)		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Yunlong Liu, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Jinghui Li, Team Member; Lily Jin, Team Member; Bernardita Saez, Project Counsel; Jinghui Li, Project admin		
Completed Site Visits by AIIB:	Apr, 2022 A joint virtual mission was held during April 10-12 to review the progress of HEAL2 and HEAL2-AF Jul, 2022 Regular update meetings which are held every two weeks on matters including the disbursement, procurement of vaccines, and project financial management. Jun, 2022 Regular update meetings which are held every two weeks on matters including the disbursement, procurement of vaccines, and project financial management. May, 2022 Regular update meetings which are held every two weeks on matters including the disbursement, procurement of vaccines, and project financial management. Sep, 2022 Regular update meetings which are held every two weeks on matters including the disbursement, procurement of vaccines, and project financial management.		
Planned Site Visits by AIIB:	Nov, 2022 Joint mission planned for the Nov 2022		
Current Red Flags Assigned:	1		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	0		
Previous Red Flags Assigned Date:	2022/04		

### 2. Project Summary and Objectives

Project objective is to support the Government of the Philippines for procurement of eligible COVID-19 vaccines. This Project is supported under AIIB's COVID-19 Crisis Recovery Facility and co-financed with the Asian Development

Bank (ADB) for the procurement of vaccines eligible under ADB's Asia Pacific Vaccine Access Facility (APVAX) program. The Project will provide critically needed vaccines to assist the Government of the Philippines in mitigating adverse health, social, and economic impacts caused by the COVID-19 pandemic.

### 3. Key Dates

Approval:	Dec. 16, 2021	Signing:	Dec. 20, 2021
Effective:	Jan. 27, 2022	Restructured (if any):	
Orig. Closing:	Sep. 30, 2024	Rev. Closing (if any):	

### 4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	0.00	Most recent disbursement (amount/date):	
Undisbursed:	250.00	Disbursement Ratio (%) <sup>1</sup> :	0.00

### 5. Project Implementation Update

(HEAL 2) The Parent Project:

ADB and AIIB are actively working with the Government of the Philippines to monitor the Project during implementation. AIIB receives regular updates on the Project through joining the bi-weekly meetings together with ADB and the implementing agency. To date, 85.63 million vaccine doses have been procured and received, and 97.89% of procured doses were delivered to the recipients. Among them, 60.5 million doses were administered. Under HEAL 2, following is the disbursement Summary as of October 28th:

Disbursed: 295.63

Undisbursed: 4.37

Disbursement Ratio (%): 98.54

(HEAL2 AF) Additional Financing:

There have been no procurement of vaccines or disbursement under the additional financing Project as of the end of October 2022

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	(HEAL 2) To date, 85.63 million doses of vaccine were procured, 100% of procured doses were received, and 97.89% of	The loan is co-financed with ADB as the lead co-financier, and the Project's environmental and social (ES) risks and impacts have been assessed in accordance with ADB's Safeguard Policy Statement (SPS).	(HEAL 2) Vaccine procurement has been made through direct procurement by the Government of Philippines with qualified suppliers. The

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

	<p>procured doses were delivered to the recipients. Among them 60.5 million doses were administered.</p> <p>the Vaccine Information Management System (VIMS) implementation is progressing and is well underway. The Department of Information Communications Technology (DICT) is actively providing training and support regionally and at contact centers.</p> <p>(HEAL 2 AF) None</p>	<p>ADB has categorized the project under its 2009 SPS as Category C for Environment, Involuntary Resettlement, and Indigenous Peoples.</p> <p>(HEAL 2) The distribution and use of COVID 19 vaccines are expected to result in a temporary increase in immunization waste generation at the point of use. However, the contract of the Integrated Waste Management Inc. (IWMI) with the Department of Health (DOH) as the service provider for the reverse logistics of used COVID-19 vaccine vials and hauling, treatment, and disposal of all COVID-19 vaccination-related wastes ended on December 31, 2021. The Special Permit to Transport (SPTT) for COVID-19 immunization wastes of DOH also ended on December 31, 2021. As the procurement of the new service provider is still ongoing, as of Aug 31, about 20.8% of the total waste has been treated and disposed of. The remaining 79.2% were either stored in the storage facilities or were safely buried in septic vaults. DOH got a new SPTT on July 25, 2022, its validity period will be ended at December 31, 2022.</p> <p>(HEAL 2 AF) N/A</p>	<p>contracts are reviewed by ADB and AIIB before making direct payments to the suppliers, with no-objection letters issued by the ADB.</p> <p>(HEAL 2 AF) No progress.</p>
--	---	--	--

**Financial Management:**

The overall Project financial management remains adequate. The Project audit report, which was due on June 30, 2022, remains outstanding. ADB informed that due to staff changes in Commission on Audit (COA), the Project audit could not be completed by the due date. Further ADB informed that if the Project audit report is not submitted by the end of 2022, ADB may suspend disbursement of the Project.

**6. Status of the Grievance Redress Mechanism (GRM)**

The parent Project GRM is active, and two environmental complaints were received. Both are on waste management: (i) Waste storage facility can easily be accessed by anyone; and (ii) No collection of wastes done by Department of Health (DOH) Central Office since January 2022, leaving no space for storage. ADB and AIIB are closely monitoring the situation.

**7. Results Monitoring**

Details can be found below:

**Project Objective Indicators #1**

Number of people vaccinated against COVID-19 (Unit: Million)

Year	Target	Actual	Comments, if any
Oct. 01, 2024	100	73	HEAL 2 target is 50 HEAL 2 AF target is 50

**Intermediate Result Indicators #1**

Vaccine Information Management System (VIMS) launched

Year	Target	Actual	Comments, if any
Jan. 01, 2024	YES	All DOH Regional Offices has adopted the Vaccine Information Management System (VIMS) for a standardized reporting of vaccination activities	The Department of Information and Communications Technology (DICT) has worked closely with the National Vaccine Operations Center (NVOC) which is tasked to analyze and report on vaccine supply and inoculation through National Covid-19 Vaccine Dashboard. VIMS in its basic format is in operation and is being further developed with more capabilities. Data is being collected from various sites through existing systems. The system is continually updated.

**Intermediate Result Indicators #2**

Doses of COVID-19 vaccines procured and delivered to the country (Unit: Million)

Year	Target	Actual	Comments, if any
Oct. 01, 2024	150	85.63 m doses	A total of at least 150 million doses of COVID-19 vaccines are to be procured under the HEAL2 and the HEAL2-AF

**Intermediate Result Indicators #3**

Gender and socially inclusive protocol and guidelines on the deployment and administration of vaccines, addressing the specific needs of marginalized women and women in especially difficult circumstances, developed, approved, and disseminated.

Year	Target	Actual	Comments, if any
Jan. 01, 2024	Yes	The DOH has issued a Department Memorandum (DM) No. 2021-0259 or the "Implementing Guidelines for Priority Groups A4, A5 and Further Clarification of the National Deployment and Vaccination Plan	On going and on track

		<p>for COVID-19 Vaccines", dated 31 May 2021. The DM covers the processes of vaccination of the A5 priority group: from master listing, vaccination scheduling and administration, and addressing barriers in implementation. All the Local Government Units (LGUs) support the policy by implementing the vaccination of poor populations nationwide. It is noteworthy that the City Government of Muntinlupa has issued an Executive Order No. 19 "Providing for Guidelines in the administration of vaccines against COVID-19 among qualified segments of the population that fall under category A5" on June 17, 2021. It highlights the vaccination of the indigent population which includes members of 4Ps, marginalized sector and the economically vulnerable population.</p>	
--	--	--	--

Remarks: